Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment

被引:20
|
作者
Lachowiez, Curtis A. [1 ]
Reville, Patrick K. [1 ]
Kantarjian, Hagop [2 ]
Jabbour, Elias [2 ]
Borthakur, Gautam [2 ]
Daver, Naval [2 ]
Issa, Ghayas [2 ]
Furudate, Ken [3 ]
Tanaka, Tomoyuki [3 ]
Pierce, Sherry [2 ]
Tang, Guilin [4 ]
Patel, Keyur P.
Medeiros, Jeffrey
Abbas, Hussein A. [2 ]
Haddad, Fadi [2 ]
Hammond, Daniel [2 ]
Short, Nicholas J. [2 ]
Maiti, Abhishek [2 ]
Yilmaz, Musa [2 ]
Sasaki, Koji [2 ]
Takahashi, Koichi [2 ]
Pemmaraju, Naveen [2 ]
Konopleva, Marina [2 ]
Garcia-Manero, Guillermo [2 ]
Ravandi, Farhad [2 ]
Kadia, Tapan M. [2 ]
Loghavi, Sanam [4 ]
DiNardo, Courtney D. [2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept hematopathol, Houston, TX 77030 USA
关键词
PROGNOSTIC-SIGNIFICANCE; AML; RECOMMENDATIONS; AZACITIDINE; DIAGNOSIS;
D O I
10.1002/ajh.26694
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutations occur frequently in newly diagnosed (ND) acute myeloid leukemia (AML) often with co-occurring NPM1 mutations, which may influence treatment outcomes. Detailed analysis of IDH-mutated AML treated with venetoclax and influence of co-occurring NPM1 mutations remains unclear. This retrospective single-center cohort study evaluated clinical and molecular demographics,response and survival, and impact of co-occurring NPM1 mutations in patients with IDH1 or IDH2-mutated AML. 556 patients with IDH1, IDH2, and/or NPM1 mutated AML were included. Patients with IDH1(mut) AML (N = 119) were more likely to have older age, sAML, ELN-adverse risk disease, and adverse-risk cytogenetics compared to those with IDH2(mut) (N = 229) or IDHwt/NPM1(mut) AML (N = 208). In multivariate analysis, patients with IDH2(mut) (HR 0.61 [95%CI: 0.43-0.88], p value: .007) or IDHwt/NPM1(mut) (HR 0.65 [95% CI: 0.45-0.94], p value: .024) AML had a decreased risk of death versus IDH1(mut) AML. Venetoclax-based lower-intensity regimens partially abrogated the detrimental effect of IDH1(mut) with similar OS observed between IDH1(mut)/NPM1(wt), IDH2(mut)/NPM1(wt), and IDHwt/NPM1(mut) AML. With regards to the influence of IDHmut/NPM1(mut) cases, IC improved survival in IDH2(mut)/NPM1(mut) versus IDH2(mut)/NPM1(wt) AML (HR: 0.54 [95% CI: 0.2644-1.082], p value: .077), while venetoclax-based therapy improved survival in IDH1(mut)/NPM1(mut) versus IDH1(mut)/NPM1(wt) AML (HR: 0.094 [95% CI: 0.01-0.74], p value: .0056). Differing outcomes were observed in IDH1(mut) versus IDH2(mut) or NPM1(mut) AML which were influenced by co-occurring NPM1 mutations and partially abrogated with venetoclax-based therapy. Given the differing biology and survival in IDH1(mut) AML, investigations incorporating molecularly targeted therapies such as IDH inhibitors remain warranted in this subgroup.
引用
收藏
页码:1443 / 1452
页数:10
相关论文
共 42 条
  • [1] Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia
    Khan, Maliha
    Cortes, Jorge
    Kadia, Tapan
    Naqvi, Kiran
    Brandt, Mark
    Pierce, Sherry
    Patel, Keyur P.
    Borthakur, Gautam
    Ravandi, Farhad
    Konopleva, Marina
    Kornblau, Steven
    Kantarjian, Hagop
    Bhalla, Kapil
    DiNardo, Courtney D.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (08)
  • [2] Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia
    Greiner, Jochen
    Mohamed, Eithar
    Fletcher, Daniel M.
    Schuler, Patrick J.
    Schrezenmeier, Hubert
    Goetz, Marlies
    Guinn, Barbara-ann
    CANCERS, 2024, 16 (20)
  • [3] Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A
    Jo, Su Yeon
    Park, Sang Hyuk
    Kim, In-Suk
    Yi, Jongyoun
    Kim, Hyung-Hoi
    Chang, Chulhun L.
    Lee, Eun Yup
    Cho, Young-Uk
    Jang, Seongsoo
    Park, Chan-Jeoung
    Chi, Hyun-Sook
    ANNALS OF LABORATORY MEDICINE, 2016, 36 (05) : 399 - 404
  • [4] Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy
    Venugopal, Sangeetha
    Shoukier, Mahran
    Konopleva, Marina
    Dinardo, Courtney D.
    Ravandi, Farhad
    Short, Nicholas J.
    Andreeff, Michael
    Borthakur, Gautam
    Daver, Naval
    Pemmaraju, Naveen
    Sasaki, Koji
    Montalban-Bravo, Guillermo
    Marx, Kayleigh R.
    Pierce, Sherry
    Popat, Uday R.
    Shpall, Elizabeth J.
    Kanagal-Shamanna, Rashmi
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    CANCER, 2021, 127 (19) : 3541 - 3551
  • [5] Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia
    Schnittger, S.
    Bacher, U.
    Kern, W.
    Alpermann, T.
    Haferlach, C.
    Haferlach, T.
    LEUKEMIA, 2011, 25 (08) : 1297 - 1304
  • [6] Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
    Onate, Guadalupe
    Bataller, Alex
    Garrido, Ana
    Hoyos, Montserrat
    Arnan, Montserrat
    Vives, Susana
    Coll, Rosa
    Tormo, Mar
    Sampol, Antonia
    Escoda, Lourdes
    Salamero, Olga
    Garcia, Antoni
    Bargay, Joan
    Aljarilla, Alba
    Nomdedeu, Josep F.
    Esteve, Jordi
    Sierra, Jorge
    Pratcorona, Marta
    BLOOD ADVANCES, 2022, 6 (03) : 882 - 890
  • [7] Prognostic Impact of NPM1 Mutations in Serbian Adult Patients with Acute Myeloid Leukemia
    Kuzmanovic, Milos
    Tosic, Natasa
    Colovic, Natasa
    Karan-Djurasevic, Teodora
    Spasovski, Vesna
    Radmilovic, Milena
    Nikcevic, Gordana
    Suvajdzic-Vukovic, Nada
    Tomin, Dragica
    Vidovic, Ana
    Virijevic, Marijana
    Pavlovic, Sonja
    Colovic, Milica
    ACTA HAEMATOLOGICA, 2012, 128 (04) : 203 - 212
  • [8] Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia
    S Schnittger
    U Bacher
    W Kern
    T Alpermann
    C Haferlach
    T Haferlach
    Leukemia, 2011, 25 : 1297 - 1304
  • [9] IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation
    Yamaguchi, Shunichiro
    Iwanaga, Eisaku
    Tokunaga, Kenji
    Nanri, Tomoko
    Shimomura, Taizo
    Suzushima, Hitoshi
    Mitsuya, Hiroaki
    Asou, Norio
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (06) : 471 - 477
  • [10] Prognostic Impact of Nucleophosmin 1 (NPM1) Gene Mutations in Egyptian Acute Myeloid Leukemia Patients
    Zidan, Magda
    Shaaban, Howyda
    El Ghannam, Doaa
    TURKISH JOURNAL OF HEMATOLOGY, 2013, 30 (02) : 129 - 136